Anitocabtagene autoleucel

美国旧金山，2026 年美国生物制造峰会现场，吉利德旗下 Kite Pharma 高级副总裁、全球技术运营负责人 Laura Alquist 在接受 FiercePharma 独家专访时，完整披露了公司 CAR-T 疗法的制造战略升级全貌，以及针对下一代产品与前沿技术的全线布局。 作为全球 CAR-T 赛道的二号玩家，Kite 曾与一众先行者一同经历了细胞治疗商业化初期的 “理想与现实落差”—— 产能瓶颈、病毒载体供应短缺、技术转移不畅、患者可及性受限等难题，一度让这款具有治愈潜力的抗癌疗法陷入 “叫好不叫座” 的困境。 而如今，随着旗下第三款 CAR-T 疗法 anito-cel 的上市审批进入倒计时，Kite 已完成从生产战略重构到商业化产能落地的全链条备战；同时，其重金押注的体内 CAR-T（in vivo CAR-T）技术，更被视作颠覆整个行业格局的关键变量。复盘初代商业化阵痛：Kite 的四大制造核心教训 在 CAR-T 疗法商业化的早期，整个行业都踩过同一个坑：技术上实现了从 0 到 1 的突破，却在从 1 到 100 的规模化生产上栽了跟头，Kite 也不例外。 凭借首款产品 Yescarta 拿下 B 细胞淋巴瘤适应症、成为全球第二家上市 CAR-T 疗法的企业后，Kite 很快直面行业共性难题：有限的生产产能、病毒载体供应链的 “卡脖子”、临床到商业化的技术转移断层，叠加患者群体分散、诊疗基础设施不足，让这款治愈性疗法的商业化落地举步维艰。 “一路走来，我们积累了深刻的经验教训。”Alquist 在专访中直言，而这些教训，最终沉淀为 Kite 制造战略的四大核心原则，也成为其穿越行业周期的核心护城河。 第一，研发与工艺开发的早期深度协同。Kite 打破了传统制药 “研发 - 工艺 - 生产” 的线性接力模式，通过临床生产团队与工艺开发（PD）团队同址办公，实现了从研发到工艺开发、再到临床生产的无缝衔接。这一调整不仅大幅简化了技术转移流程、加快了产品进入临床的速度，更从研发早期就将商业化规模化生产的需求纳入考量，彻底解决了 “实验室成果难落地量产” 的行业痛点。 第二，在上市速度与工艺稳健性之间找到精准平衡。“对于能改变患者命运、甚至实现治愈的疗法而言，上市速度至关重要。”Alquist 坦言，工艺的稳健性优化可以持续进行，但有时会以牺牲上市速度为代价。而 Kite 的核心原则，是在保障产品质量的前提下，优先让患者尽早用上创新疗法，后续再持续迭代优化生产工艺。这一思路，也让 Yescarta、Tecartus 两款产品先后完成多次适应症拓展，快速覆盖更多患者群体。 第三，病毒载体生产全面内生化，筑牢供应链护城河。初代 CAR-T 商业化的最大瓶颈之一，就是核心原料病毒载体的供应短缺 —— 早期 Kite 完全依赖外包生产，不仅产能受限，供应链稳定性也难以保障。2019 年，Kite 宣布在加州欧申赛德生物制药基地建设 6.7 万平方英尺的病毒载体生产工厂，全面实现载体生产内生化。 如今，Kite 的自有产能不仅能稳定供应逆转录病毒载体，支撑全线商业化产品与临床管线，还在推进慢病毒载体的生产工艺升级，为下一代产品提供全链条支持。Alquist 直言，自有载体产能，是保障公司商业化与临床管线稳定推进的核心基石。 第四，全球化产能网络搭建，实现区域化就近供应。截至目前，Kite 已经建成了位于美国南加州、马里兰州弗雷德里克、荷兰阿姆斯特丹的三大商业化生产基地，配套日本分销中心，形成了覆盖北美、欧洲、中东与亚太市场的全球最大自有细胞治疗生产网络。2022 年弗雷德里克工厂获 FDA 批准后，这一网络的规模化能力再上台阶。anito-cel 上市进入倒计时，商业化产能已全面就绪 制造体系的全面升级，最终要落地到产品的商业化落地。当下，Kite 的核心备战目标，是与 Arcellx 合作开发的 BCMA CAR-T 疗法 anito-cel—— 这款针对多发性骨髓瘤的下一代产品，预计将于 2026 年底迎来 FDA 的上市审批决定。 这将是 Kite 旗下的第三款 CAR-T 疗法，也是其首次进军多发性骨髓瘤赛道，将与 Yescarta（B 细胞淋巴瘤）、Tecartus（套细胞淋巴瘤、急性淋巴细胞白血病）形成产品矩阵的全面互补，填补其在血液肿瘤核心适应症的布局空白。 Alquist 透露，早在临床阶段，Kite 就已锁定马里兰州弗雷德里克工厂作为 anito-cel 的核心生产基地。目前该工厂已顺利完成临床阶段的产品供应，正在全力推进商业化放量的准备工作，确保产品获批后即可 “全速落地”，实现上市即规模化供应。 值得关注的是，anito-cel 的患者细胞制备周期仅为 14-17 天，与已实现商业化的 Yescarta 相当。在自体 CAR-T 疗法的竞争中，制备周期是核心竞争力之一 —— 更短的周期，意味着能为病情进展迅速的晚期肿瘤患者争取更多治疗窗口，同时也能降低生产与物流环节的成本与风险。押注体内 CAR-T，锁定行业下一个十年的颠覆性变革 如果说 anito-cel 的备战，是 Kite 在现有自体 CAR-T 赛道的 “守成与扩容”，那么其对体内 CAR-T 技术的全线布局，则是瞄准了细胞治疗行业的下一场革命。 “体内 CAR-T 的潜力是极具颠覆性的，我们正处在另一场重大突破的临界点。”Alquist 在专访中毫不掩饰对这一技术的期待。 传统的自体 CAR-T 疗法，需要先从患者体内分离出 T 细胞，在体外进行基因工程改造、扩增培养，再回输到患者体内。整个流程不仅生产工艺复杂、周期长，还面临着严苛的物流与冷链要求，极大地限制了患者的可及性，也让 CAR-T 疗法难以下沉到基层医疗市场。 而体内 CAR-T 疗法，通过基因治疗技术，直接在患者体内完成 T 细胞的基因修饰与激活，彻底颠覆了传统自体 CAR-T 的生产与治疗范式。它无需采集患者自身免疫细胞，也无需复杂的体外定制化生产，回归到了传统药物的规模化生产与分销模式，从根本上解决了传统 CAR-T 的生产与物流痛点。 为了抢占这一前沿赛道，Kite 与母公司吉利德已经开启了重金布局：2025 年夏天，吉利德以 3.5 亿美元收购了体内CAR-T 技术公司 Interius BioTherapeutics；同期，Kite 与中国生物科技公司 Pregene 达成合作，支付 1.2 亿美元首付款，共同推进体内 CAR-T 疗法的研发。 在 Alquist 看来，体内 CAR-T 并不会在短期内完全替代体外自体 CAR-T 疗法，“未来十年，体内与体外疗法将形成更均衡的市场格局”。但不可否认的是，体内 CAR-T 不仅能大幅提升患者可及性、让疗法更快触达患者，甚至有望免去自体 CAR-T 疗法必需的预处理化疗，进一步降低治疗的门槛与副作用。区域化布局的底层逻辑：让治愈性疗法离患者更近 除了技术与产能的布局，Kite 的全球化生产网络还有一个核心的底层逻辑：区域化布局，最大限度贴近患者。 Alquist 表示，Kite 的生产网络采用 “区域化建设” 模式，北美、欧洲均设有核心生产基地，其中欧洲基地同时覆盖中东市场，日本则设有专门的分销中心。这一布局，不仅能够应对全球地缘政治与关税政策带来的不确定性，更核心的目标，是尽可能缩短产品从生产到患者输注的距离，为患者争取宝贵的治疗时间。 毕竟，对于晚期肿瘤患者而言，每缩短一天的治疗等待时间，都意味着多一分治愈的希望。 从初代产品商业化的举步维艰，到如今建成全球最大的自有细胞治疗生产网络，再到提前布局下一代颠覆性技术，Kite 的发展历程，正是全球 CAR-T 行业从技术突破到产业成熟的缩影。 过去十年，CAR-T 疗法完成了 “从无到有” 的跨越，让血液肿瘤患者看到了治愈的可能；而未来十年，行业的核心命题，将是 “从有到广”—— 如何通过生产工艺的革新、治疗范式的升级，让这款治愈性疗法，触达全球更多有需要的患者。 而 Kite 已经用自己的行动给出了答案：技术创新的终点，永远是患者的可及性。 参考来源：https://www.fiercepharma.com/manufacturing/lessons-learned-kite-prepares-hit-ground-running-next-gen-car-t-decision-looms 识别微信二维码，添加生物制品圈小编，符合条件者即可加入 生物制品微信群！ 请注明：姓名+研究方向！ 版 权 声 明 本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and Arcellx’s successful collaboration and provides Gilead with full control of anitocabtagene autoleucel (anito‑cel), an investigational BCMA‑directed CAR T‑cell therapy for multiple myeloma. By consolidating ownership of anito‑cel and eliminating future profit‑share, milestone and royalty obligations, Gilead is positioned to accelerate development, streamline decision‑making and maximize the long‑term potential of the program. “With the Arcellx acquisition, our focus turns to executing with speed and discipline as we prepare to bring anito‑cel to patients,” said Cindy Perettie, Executive Vice President and Global Head of Kite. “I want to thank the Arcellx team for their scientific leadership, close collaboration to date and deep expertise they bring as we advance anito‑cel. With this acquisition, anito‑cel and the differentiated D‑Domain BCMA binder will advance within Kite, combining this science with our global manufacturing, regulatory and commercial capabilities to unlock the full value of this potentially transformative therapy for people living with multiple myeloma.” On April 28, 2026, Gilead successfully completed its tender offer for all outstanding shares of common stock of Arcellx and accepted for payment all shares validly tendered and not validly withdrawn as of the expiration time of the tender offer, which shares represented, together with shares already owned by Gilead, approximately 77.2% of Arcellx’s outstanding shares. Following completion of the offer, Gilead completed the acquisition of Arcellx through a merger of Gilead’s wholly owned subsidiary with and into Arcellx, in which shares of Arcellx common stock were cancelled and converted into the right to receive the same $115 per share in cash and one CVR of $5 per share as shares tendered in the offer. The CVR is payable upon achievement of cumulative global net sales of anito‑cel of at least $6.0 billion from launch through the end of 2029. As a result of the completion of the merger, Arcellx has become a wholly owned subsidiary of Gilead and the common stock of Arcellx will be delisted from the Nasdaq Global Select Market. This transaction is expected to be accounted for as an asset acquisition and reduce Gilead’s GAAP and non-GAAP 2026 diluted EPS by approximately $5.57 - $5.67. Excluding the impact of acquired in-process research and development expenses, Gilead expects the transaction to be modestly dilutive to earnings per share in 2026 and 2027, and accretive in 2028 and thereafter, subject to FDA approval of anito‑cel. About Anito-cel Anitocabtagene autoleucel (anito-cel, previously ddBCMA) is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes a novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. This combination may allow for the effective elimination of multiple myeloma cells without severe immunotoxicity. Anito-cel has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations by the U.S. Food and Drug Administration. About Gilead and Kite Oncology Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif. Forward-Looking Statements This communication contains forward-looking statements related to Gilead, Arcellx and the acquisition of Arcellx by Gilead that are subject to risks, uncertainties, and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of Gilead and Arcellx and members of their respective senior management teams. In some cases, forward-looking statements can be identified by the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “seek,” “may,” “plan,” “project,” “should,” “target,” “will,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, without limitation, statements regarding the transaction and related matters, prospective performance and opportunities, post-closing operations and the outlook for the companies’ businesses, including Gilead’s ability to apply its global manufacturing, regulatory and commercial capabilities and to accelerate the development of anito-cel; regulatory applications; the potential of Arcellx’s cell therapy platform; the impact of the transaction on Gilead’s diluted EPS; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: the effects of the transaction on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any; the risk that the businesses will not be integrated successfully and that other anticipated benefits from the transaction will not be realized; the risk that the milestone associated with the CVR may not be achieved and that holders of CVRs may not receive payments in respect thereof; the impact of competitive products and pricing; other business effects, including the effects of industry, economic or political conditions outside of the companies’ control; transaction costs; actual or contingent liabilities; and other risks and uncertainties detailed from time to time in the companies’ periodic reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 filed by Arcellx and the Schedule TO and related tender offer documents filed by Gilead and Ravens Sub, Inc., a wholly owned subsidiary of Gilead. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements. Gilead, Kite, Arcellx and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies. For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).